Your browser doesn't support javascript.
loading
STATIN USE AND THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION: A Meta-Analysis.
Eshtiaghi, Arshia; Popovic, Marko M; Sothivannan, Amirthan; Muni, Rajeev H; Kertes, Peter J.
Afiliação
  • Eshtiaghi A; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Popovic MM; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Sothivannan A; Michael G. DeGroote Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Muni RH; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Kertes PJ; Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada; and.
Retina ; 42(4): 643-652, 2022 04 01.
Article em En | MEDLINE | ID: mdl-34983903
PURPOSE: Age-related macular degeneration (AMD) shares many of the same risk factors with atherosclerosis. There is a postulated role of lipid-lowering agents in preventing AMD. This meta-analysis investigates the possible role of statins in the prevention of AMD onset and progression. METHODS: MEDLINE, EMBASE, Cochrane CENTRAL, and the reference lists of included studies were systematically searched from inception to September 2020. Studies were included if they measured the risk of AMD development or progression with statin use. The primary outcomes assessed were AMD incidence and progression. Secondary outcomes were the incidence of early AMD, late AMD, choroidal neovascularization, and geographic atrophy. RESULTS: Twenty-one articles (1 randomized control trial and 20 observational studies) collectively reporting on 1,460,989 participants were included. The pooled risk ratios (95% confidence interval) for statin use on any, early, and late AMD incidence were 1.05 (0.85-1.29) (P = 0.44), 0.99 (0.88-1.11) (P = 0.86), and 1.15 (0.90-1.47) (P = 0.27), respectively. In patients with existing AMD, the respective risk ratios for statin use on incidence of AMD progression, choroidal neovascularization, and geographic atrophy were 1.04 (0.70-1.53) (P = 0.85), 0.99 (0.66-1.48) (P = 0.95), and 0.84 (0.58-1.22) (P = 0.36). CONCLUSION: This meta-analysis found that there was no significant difference in the incidence or progression of AMD based on statin use.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Neovascularização de Coroide / Atrofia Geográfica / Degeneração Macular Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Retina Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Neovascularização de Coroide / Atrofia Geográfica / Degeneração Macular Tipo de estudo: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Retina Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá